Immunoglobulin light-chain amyloidosis
Drug research and approvals for immunoglobulin light-chain amyloidosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 49 studies of immunoglobulin light-chain amyloidosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 49
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell DisordersNCT07850284 · Not reported · Mayo Clinic · starts Aug 25, 2026
- Hungarian National Systemic Amyloidosis RegistryNCT07689331 · Not reported · Semmelweis University · starts Mar 8, 2026
- A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly…NCT07638683 · Phase 2 · Shanghai Zhongshan Hospital · starts May 22, 2026
- Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and TreatmentNCT07448779 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Nov 17, 2025
- One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMSNCT07448935 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Nov 28, 2025
- Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL AmyloidosisNCT07335887 · Phase 2 · Peking University People's Hospital · starts Feb 10, 2026
- Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL…NCT07250269 · Phase 1 · Gracell Biotechnologies (Shanghai) Co., Ltd. · starts Oct 29, 2025
- [18F]FT8 PET Imaging in Immunoglobulin Light Chain AmyloidosisNCT07232459 · Not reported · Tianjin Medical University · starts Jul 21, 2025
- A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib,…NCT07224672 · Phase 2 · GlaxoSmithKline · starts Jun 24, 2026
Phase 3 2
- DexamethasoneGlucocorticoid receptor agonist
- Bortezomib26S proteasome inhibitor
Phase 2 5
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- CyclophosphamideDNA inhibitor
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- EtanerceptTNF-alpha inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
Phase 1 or earlier 5
- MiridesapSerum amyloid P-component cross-linking agent
- DoxorubicinDNA topoisomerase II alpha inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Carfilzomib26S proteasome inhibitor
- DezamizumabSerum amyloid P-component inhibitor
How its trials ended
130 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 40 whose ending is known, 45% met their primary endpoint, 8% missed it and 48% stopped early.
- Completed, result not reported4333%
- Ongoing4333%
- Met its primary endpoint1814%
- Stopped: other or unclear118%
- Stopped: enrollment or feasibility43%
- Status unknown43%
- Missed its primary endpoint32%
- Stopped: lack of efficacy22%
- Stopped: sponsor or business decision22%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA